Welcome to our dedicated page for Tactile Systems SEC filings (Ticker: TCMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tactile Systems Technology, Inc. filings document a Nasdaq-listed medical technology issuer with common stock registered under the ticker TCMD. Recent Form 8-K reports disclose quarterly and annual operating results, financial condition updates, acquisition-related Regulation FD materials, FDA and product-related business highlights, share repurchase authorization activity and other corporate events.
The company's proxy and governance filings cover board composition, director elections, committee assignments, executive compensation, shareholder voting matters and amendments to its certificate of incorporation. Its SEC disclosures also identify Delaware incorporation, Nasdaq listing status, capital actions and governance provisions relevant to its public-company structure.
Tactile Systems Technology chief executive officer Sheri Louise Dodd reported an equity award on Common Stock. She acquired 48,672 restricted stock units at a stated price of $0.00 per share as a grant or award, bringing her directly held stake to 222,151 shares after the transaction.
The RSUs vest in three equal annual installments, with one-third becoming available on each of the first three anniversaries of the grant date. This structure ties the CEO’s compensation to continued service and the company’s long-term performance.
Burns Kristie reported acquisition or exercise transactions in this Form 4 filing.
Tactile Systems Technology senior vice president Kristie Burns reported an equity award of 6,194 shares of common stock in the form of restricted stock units. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date. After this award, she directly holds 78,595 shares of common stock, reflecting her updated ownership position in the company.
Birkemeyer Elaine M. reported acquisition or exercise transactions in this Form 4 filing.
Tactile Systems Technology chief financial officer Elaine M. Birkemeyer received a grant of 23,008 shares of common stock in the form of restricted stock units at a stated price of $0.0000 per share. Following this award, her directly held common stock position reported in this filing is 122,119 shares.
The RSUs vest over three years, with one-third of the units vesting on each of the first three anniversaries of the grant date, meaning the compensation is spread over time and depends on continued service.
Kristie Burns submitted a Form 144 notice to sell common stock. The filing lists 4,439 shares tied to restricted stock vesting on 02/20/2026 and shows $125,610.38 alongside a Fidelity brokerage record. It also reports 5,139 shares sold on 01/02/2026 for $148,260.15.
Tactile Systems Technology, Inc. reports full-year 2025 results and provides a detailed overview of its medical technology business focused on at-home treatment of chronic diseases. The company generated $329.5 million in revenue and $19.1 million in net income for 2025, with revenue growing 12% year over year.
Lymphedema products, including Flexitouch Plus, Entre Plus and Nimbl, produced $278.4 million or 84% of 2025 revenue, while the AffloVest airway clearance product line contributed $51.1 million or 16%. Tactile highlights broad U.S. reimbursement coverage, in‑network payer contracts covering about 278 million lives, and a largely direct-to-patient model for lymphedema alongside a DME distribution model for AffloVest.
The filing emphasizes extensive clinical evidence supporting Flexitouch, Nimbl and AffloVest, ongoing R&D investment of $8.5 million in 2025, and a sizable commercial organization with 166 account managers and 185 specialists as of December 31, 2025. Management also outlines significant market opportunities in lymphedema, chronic venous insufficiency and bronchiectasis, while detailing the regulatory, reimbursement and fraud-and-abuse frameworks governing its operations.
Tactile Systems Technology, Inc. reports full-year 2025 results and provides a detailed overview of its medical technology business focused on at-home treatment of chronic diseases. The company generated $329.5 million in revenue and $19.1 million in net income for 2025, with revenue growing 12% year over year.
Lymphedema products, including Flexitouch Plus, Entre Plus and Nimbl, produced $278.4 million or 84% of 2025 revenue, while the AffloVest airway clearance product line contributed $51.1 million or 16%. Tactile highlights broad U.S. reimbursement coverage, in‑network payer contracts covering about 278 million lives, and a largely direct-to-patient model for lymphedema alongside a DME distribution model for AffloVest.
The filing emphasizes extensive clinical evidence supporting Flexitouch, Nimbl and AffloVest, ongoing R&D investment of $8.5 million in 2025, and a sizable commercial organization with 166 account managers and 185 specialists as of December 31, 2025. Management also outlines significant market opportunities in lymphedema, chronic venous insufficiency and bronchiectasis, while detailing the regulatory, reimbursement and fraud-and-abuse frameworks governing its operations.
Tactile Systems Technology reported strong fourth quarter and full-year 2025 results and announced a strategic acquisition. Fourth quarter revenue rose 21% to $103.6 million, with operating income up to $18.8 million and net income of $10.6 million, or $0.46 per diluted share. Full-year 2025 revenue grew 12% to $329.5 million, driven by 7% growth in lymphedema products and 52% growth in airway clearance products. Net income increased to $19.1 million and Adjusted EBITDA rose to $44.8 million, reflecting improved profitability.
The company ended 2025 with $83.4 million in cash and no debt after repaying $26.3 million of term loan borrowings and repurchasing $26.5 million of stock. For 2026, it guides revenue to $357–$365 million and Adjusted EBITDA to $49–$51 million, implying continued growth. Separately, Tactile Medical acquired LymphaTech Inc. for an upfront cash payment of $6.8 million plus potential milestone-based consideration, adding a 3D digital measurement platform to deepen its lymphedema solutions portfolio.
Tactile Systems Technology reported strong fourth quarter and full-year 2025 results and announced a strategic acquisition. Fourth quarter revenue rose 21% to $103.6 million, with operating income up to $18.8 million and net income of $10.6 million, or $0.46 per diluted share. Full-year 2025 revenue grew 12% to $329.5 million, driven by 7% growth in lymphedema products and 52% growth in airway clearance products. Net income increased to $19.1 million and Adjusted EBITDA rose to $44.8 million, reflecting improved profitability.
The company ended 2025 with $83.4 million in cash and no debt after repaying $26.3 million of term loan borrowings and repurchasing $26.5 million of stock. For 2026, it guides revenue to $357–$365 million and Adjusted EBITDA to $49–$51 million, implying continued growth. Separately, Tactile Medical acquired LymphaTech Inc. for an upfront cash payment of $6.8 million plus potential milestone-based consideration, adding a 3D digital measurement platform to deepen its lymphedema solutions portfolio.
Cadian Capital filed an amended Schedule 13G/A showing passive ownership in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Cadian Capital Management, its general partner, and Eric Bannasch were deemed to beneficially own 1,084,094 shares, or about 4.9% of the outstanding common stock.
All shares are held by advisory clients of Cadian Capital Management, over which the adviser has shared voting and investment power. The filing certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Cadian Capital filed an amended Schedule 13G/A showing passive ownership in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Cadian Capital Management, its general partner, and Eric Bannasch were deemed to beneficially own 1,084,094 shares, or about 4.9% of the outstanding common stock.
All shares are held by advisory clients of Cadian Capital Management, over which the adviser has shared voting and investment power. The filing certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Paradigm Capital Management, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Paradigm beneficially owned 736,599 shares, representing 3.29% of the company’s common stock, with sole voting and dispositive power.
The firm states the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Tactile Systems Technology.